TLX — Telix Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$4.41bn
- AU$4.30bn
- AU$502.55m
Annual cashflow statement for Telix Pharmaceuticals, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 9.36 | 11.5 | 12.1 | 18.9 | -14.7 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -23.3 | 1.96 | -59.3 | -64 | 23.9 |
| Capital Expenditures | -0.468 | -0.322 | -1.34 | -13.9 | -10.8 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | -0.769 | -1.39 | -3.14 | -14.7 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.468 | -1.09 | -2.73 | -17 | -25.5 |
| Financing Cash Flow Items | -1.36 | -0.13 | 0 | -7.82 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 42.7 | 34.1 | 2.85 | 175 | 10.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 18.8 | 33.3 | -55.9 | 94.3 | 6.91 |